DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
DermTech Stock Performance
DMTK opened at $6.80 on Friday. The stock has a market cap of $204.27 million, a price-to-earnings ratio of -1.91 and a beta of 1.40. The stock's 50 day moving average price is $6.44 and its 200-day moving average price is $9.55. DermTech has a one year low of $4.18 and a one year high of $38.97.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on DMTK. BTIG Research reduced their price objective on DermTech from $38.00 to $19.00 and set a "buy" rating on the stock in a research note on Tuesday, June 14th. Cowen reduced their price objective on DermTech from $33.00 to $20.00 in a research note on Wednesday, May 4th. Lake Street Capital reduced their price objective on DermTech from $34.00 to $14.00 in a research note on Tuesday, August 9th. Oppenheimer reissued an "outperform" rating and set a $48.00 price objective on shares of DermTech in a research note on Monday, July 18th. Finally, Craig Hallum reduced their price objective on DermTech from $37.00 to $18.00 in a research note on Tuesday, August 9th.